Endoskeletal nanodrops for x-ray acoustic dosimetry

用于 X 射线声剂量测定的内骨骼纳米滴

基本信息

批准号：
10660977
负责人：
Mark Andrew Borden
金额：
$ 16.74万
依托单位：
UNIVERSITY OF COLORADO DENVER
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-07-15 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10660977
关键词：
3-Dimensional Acoustics Algorithms Anatomy Body Weight decreased Cancer Patient Clinical Clinical Trials Contrast Media Contrast Sensitivity Data Detection Devices Dose Drops Dyes Fatty acid glycerol esters Fluorocarbons Formulation Future Geometry Goals Heating Hydrocarbons Image Ions Linear Accelerator Radiotherapy Systems Liquid substance Measurement Measures Medical Metals Methods Microbubbles Noise Normal tissue morphology Patient-Focused Outcomes Patients Phase Photons Physiologic pulse Preclinical Testing Publications Radiation Radiation Dose Unit Radiation therapy Radiometry Reproducibility Research Roentgen Rays Signal Transduction Skeleton Solid Structure System Techniques Technology Time Tissues Toxic effect Treatment outcome Tumor Volume Ultrasonography United States Work X-Ray Computed Tomography absorption cancer therapy clinical translation commercialization contrast enhanced design dosimetry experimental study imaging agent improved improved outcome in vivo interest invention melting novel particle radiation delivery rapid growth reconstruction response side effect simulation skeletal treatment planning tumor ultrasound vaporization

项目摘要

PROJECT SUMMARY More than half of all cancer patients in the United States receive Radiation Therapy (RT) as a part of their cancer treatment (>500,000 patients per year). Cancer patients typically receive a highly targeted dose of radiation over the course of days or weeks. Each patient will typically receive 25-40 daily treatments. Treatment outcome is dependent on accurate delivery of radiation. All RT patient treatment plans are based on a planning `simulation' CT scan, acquired days or weeks before the start of treatment. However, due to weight loss or tumor shrinkage in the time between simulation and treatment, anatomical changes may lead to healthy tissues being irradiated. Side effects of irradiating healthy tissue can be severe. Adaptive optimizing has chance . However, the implementation of ART is severely limited by the lack of a real-time device that can accurately measure the delivered radiation distribution within the patient. Currently no system exists which is capable of measuring the radiation dose distribution within the patient. RT (ART) – re- the radiation distribution based on the patient's daily anatomy in order to maintain the plan quality – been proposed as a means to deliver more radiation with reduced normal tissue damage; increasing the of a cure, with fewer side effects This project will address this need by developing the first contrast agent for imaging radiation therapy. Our approach will employ the x-ray acoustic (XA) effect, which is analogous to the “photoacoustic effect”, a physical phenomenon whereby acoustic waves are generated by the absorption of heat energy from a pulsed photon beam. In XA Computed Tomography (XACT), the photon beam is high-energy x-ray radiation generated by a medical linear accelerator (LINAC) used in clinical radiation therapy. Novel XA contrast agents are needed to improve XACT imaging and are essential to our concept of XACT dosimetry. Toward this end, we recently invented vaporizable endoskeletal drops (VEDs) comprising a liquid fluorocarbon droplet with a solid hydrocarbon “skeleton”. We discovered that the liquid fluorocarbon droplet vaporizes upon heating and melting of the hydrocarbon solid. The drop-to-bubble expansion emits an acoustic wave that can be imaged with XACT, and the resulting microbubble is echogenic for ultrasound imaging. This project will develop the VED technology into a novel radiation therapy contrast agent for XACT by 1) Formulation of VEDs comprising high-z metal ions within the hydrocarbon skeletal phase to absorb x-rays and stimulate vaporization; and 2) Measurement of the XA effect of high-z VEDs. Completing these aims will enable future commercialization, in vivo preclinical testing, and clinical translation.

项目概要美国超过一半的癌症患者接受放射治疗 (RT) 作为其治疗的一部分癌症治疗（每年超过 500,000 名患者）通常接受高度针对性的剂量。每位患者通常每天接受 25-40 次治疗。治疗结果取决于准确的放射治疗。所有 RT 患者治疗计划均基于此。计划“模拟”CT 扫描，在治疗开始前几天或几周进行，但是，由于体重的原因。在模拟和治疗之间的时间内肿瘤丢失或缩小，解剖结构的变化可能会导致健康照射健康组织的副作用可能很严重。优化有然而，ART 的实施因缺乏机会而受到严重限制。目前可以准确测量患者体内的辐射分布的实时设备。不存在能够测量患者体内辐射剂量分布的系统。 RT (ART) – 重新基于患者日常解剖结构的辐射分布，以保持计划质量 – 已被提议作为一种提供更多辐射并减少正常组织损伤的方法；治愈的方法，副作用更少该项目将通过开发第一种用于成像放射治疗的造影剂来满足这一需求。方法将利用 X 射线声学 (XA) 效应，这类似于“光声效应”，一种物理效应。通过吸收脉冲光子的热能而产生声波的现象在 XA 计算机断层扫描 (XACT) 中，光子束是由 X 射线产生的高能 X 射线辐射。临床放射治疗需要新型 XA 造影剂。改进 XACT 成像，这对于我们的 XACT 剂量测定概念至关重要。最近发明的可汽化内骨骼液滴（VED）包含液体碳氟化合物液滴和固体我们发现液态碳氟化合物液滴在加热和熔化时会蒸发。碳氢化合物固体的液滴膨胀会发出声波，可以用它来成像。 XACT，产生的微泡具有回声功能，可用于超声成像。该项目将开发 VED。通过 1) 配制包含高 z 值的 VED，将技术转化为用于 XACT 的新型放射治疗造影剂碳氢化合物骨架相内的金属离子吸收 X 射线并刺激汽化；2) 测量高 z VED 的 XA 效应将使未来的商业化成为可能。体内临床前测试和临床转化。